- Home
- KN vs ADPT Comparison
KN vs ADPT Comparison
Compare KN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KN
- ADPT
- Stock Information
- Founded
- KN 1946
- ADPT 2009
- Country
- KN United States
- ADPT United States
- Employees
- KN N/A
- ADPT N/A
- Industry
- KN Consumer Electronics/Appliances
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KN Consumer Staples
- ADPT Health Care
- Exchange
- KN Nasdaq
- ADPT Nasdaq
- Market Cap
- KN 2.0B
- ADPT 2.0B
- IPO Year
- KN N/A
- ADPT 2019
- Fundamental
- Price
- KN $23.61
- ADPT $17.11
- Analyst Decision
- KN Buy
- ADPT Strong Buy
- Analyst Count
- KN 3
- ADPT 10
- Target Price
- KN $21.00
- ADPT $14.10
- AVG Volume (30 Days)
- KN 645.8K
- ADPT 2.0M
- Earning Date
- KN 10-23-2025
- ADPT 11-06-2025
- Dividend Yield
- KN N/A
- ADPT N/A
- EPS Growth
- KN N/A
- ADPT N/A
- EPS
- KN 0.28
- ADPT N/A
- Revenue
- KN $563,100,000.00
- ADPT $205,216,000.00
- Revenue This Year
- KN $8.20
- ADPT $32.63
- Revenue Next Year
- KN $5.13
- ADPT $16.31
- P/E Ratio
- KN $84.45
- ADPT N/A
- Revenue Growth
- KN 9.17
- ADPT 21.60
- 52 Week Low
- KN $12.19
- ADPT $4.27
- 52 Week High
- KN $24.54
- ADPT $17.10
- Technical
- Relative Strength Index (RSI)
- KN 57.59
- ADPT 74.19
- Support Level
- KN $22.27
- ADPT $15.21
- Resistance Level
- KN $23.77
- ADPT $15.94
- Average True Range (ATR)
- KN 0.69
- ADPT 0.70
- MACD
- KN -0.16
- ADPT 0.17
- Stochastic Oscillator
- KN 56.95
- ADPT 98.91
About KN Knowles Corporation
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).